Références
1.
HAS. Commission de transparence. 19 mars 2008.
2.
Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D'Amico R.
Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst
Rev. 2012 Apr 18;4:CD006243.
3.
Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M,
Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A,
Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z,
Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R; Herceptin
Adjuvant (HERA) Trial Study Team. Treatment with trastuzumab for 1 year after
adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year
follow-up of a randomised controlled trial. Lancet Oncol. 2011 Mar;12(3):236-44.
4.
Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S,
Mamounas EP, Kaufman PA, Wolmark N. Four-year follow-up of trastuzumab plus
adjuvant chemotherapy for operable human epidermal growth factor receptor 2-
positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J
Clin Oncol. 2011 Sep 1;29(25):3366-73.
5.
Slamon DJ, Eiermann W, Robert NJ, Giermek J, Martin M, Jasiowka M, Mackey JR,
Chan A, Liu MC, Pinter T, Valero V, Falkson C, Fornander T, Shiftan TA, Bensfia
S, Hitier S, Xu N, Bée-Munteanu V, Drevot P, Press MF, Crown J. Ten year follow-
up of the BCIRG-006 trial comparing doxorubicin plus cyclophosphamide followed
by docetaxel with doxorubicin plus cyclophosphamide followed by docetaxel and
trastuzumab with docetaxel, carboplatin and trastuzumab in HER+ early breast cancer
patients. SABCS 2015, S5-04.
6.
Jones SE, Collea R, Paul D, Sedlacek S, Favret AM, Gore I Jr, Lindquist DL, Holmes
FA, Allison MA, Brooks BD, Portillo RM, Vukelja SJ, Steinberg MS, Stokoe C,
Crockett MW, Wang Y, Asmar L, Robert NJ, O'Shaughnessy J. Adjuvant docetaxel
and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage
breast cancer: a single-group, open-label, phase 2 study. Lancet Oncol. 2013
Oct;14(11):1121-8.
4
